反硫化
同型半胱氨酸
转甲基
内科学
内分泌学
蛋氨酸
高同型半胱氨酸血症
胱硫醚β合酶
肾功能
同型半胱氨酸尿
医学
肌酐
生物化学
化学
氨基酸
作者
Coen van Guldener,Coen D.A. Stehouwer
出处
期刊:Seminars in Vascular Medicine
[Georg Thieme Verlag KG]
日期:2005-05-01
卷期号:5 (02): 201-208
被引量:35
标识
DOI:10.1055/s-2005-872405
摘要
Renal insufficiency is invariably accompanied by elevated plasma concentrations of the sulfur-containing and potentially vasculotoxic amino acid homocysteine. There is a strong relationship between glomerular filtration rate and plasma homocysteine concentration. Unlike creatinine, however, homocysteine is avidly reabsorbed in the renal tubules, and its urinary excretion is minimal. There is no evidence that homocysteine is actively removed by the human kidney. In renal insufficiency, plasma concentrations of S-adenosylmethionine, S-adenosylhomocysteine, cystathionine, cysteine, and sulfate are elevated, pointing to a remethylation or distal transsulfuration/oxidation block as the cause of hyperhomocysteinemia in renal failure. Stable isotope techniques have shown that both whole-body homocysteine remethylation and methionine transmethylation are decreased in renal failure, whereas homocysteine transsulfuration seems intact. Metabolic homocysteine clearance (i.e., transsulfuration relative to plasma homocysteine) is decreased to a major extent. These metabolic disturbances in renal failure can only be partially restored with current treatments. Folic acid treatment lowers plasma homocysteine concentration and increases remethylation and transmethylation rates. Plasma homocysteine, however, is not normalized, and metabolic homocysteine clearance by transsulfuration remains impaired. According to the currently available data, effective normalization of plasma homocysteine can only be obtained when its metabolic clearance through transsulfuration is restored.
科研通智能强力驱动
Strongly Powered by AbleSci AI